Joincare Pharmaceutical Group Industry Co Ltd 2022 AR2
The report highlights Joincare's steady performance in 2022, achieving total revenues of RMB 17,143 million, a year-on-year increase of 7.79%. The company made significant progress in its R&D pipeline, with Tobramycin Inhalation Solution approved for market launch and the Recombinant SARS-CoV-2 Fusion Protein Vaccine included for emergency booster vaccination. Joincare also successfully listed its Global Depository Receipts on the SIX Swiss Exchange, becoming the first domestic bio-pharmaceutical enterprise to do so. Additionally, the company integrated ESG concepts into its operations, introducing carbon emission targets to achieve carbon neutrality by 2055 and donating RMB 12.117 million to social welfare.
Company: Joincare Pharmaceutical Group Industry Co Ltd
Sector: Health Care
Country: China
Year: 2022
Type: AR2
Pages: 294
Joincare Pharmaceutical Group Industry Co Ltd
Annual Report
The report highlights Joincare's steady performance in 2022, achieving total revenues of RMB 17,143 million, a year-on-year increase of 7.79%. The company made significant progress in its R&D pipeline, with Tobramycin Inhalation Solution approved for market launch and the Recombinant SARS-CoV-2 Fusion Protein Vaccine included for emergency booster vaccination. Joincare also successfully listed its Global Depository Receipts on the SIX Swiss Exchange, becoming the first domestic bio-pharmaceutical enterprise to do so. Additionally, the company integrated ESG concepts into its operations, introducing carbon emission targets to achieve carbon neutrality by 2055 and donating RMB 12.117 million to social welfare.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Net Zero Target
Employees